Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
- Authors
- Qin, SK[Qin, Shukui]; Fang, WJ[Fang, Weijia]; Ren, ZG[Ren, ZhengGang]; Shuangyan, O[Shuangyan, Ou]; Lim, HY[Lim, Ho Yeong]; Zhang, F[Zhang, Feng]; Choi, HJ[Choi, Hye Jin]; Tong, JD[Tong, Jiandong]; Tao, M[Tao, Min]; Xu, AB[Xu, Aibing]; Cheng, ACK[Cheng, Ashley Chi Kin]; Lu, CH[Lu, Chang-Hsien]; Chiu, CF[Chiu, Chang-Fang]; Wahid, MIA[Wahid, Mohamed Ibrahim A.]; Kamble, S[Kamble, Shital]; Norquist, JM[Norquist, Josephine M.]; Zhong, WY[Zhong, Wen Yan]; Li, C[Li, Chen]; Chen, ZD[Chen, Zhendong]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.